Illumina (ILMN) Tops Q3 EPS by 25c
Illumina (NASDAQ: ILMN) reported Q3 EPS of $1.02, $0.25 better than the analyst estimate of $0.77. Revenue for the quarter came in at $794 million versus the consensus estimate of $715.91 million.
“Our business accelerated in the third quarter with sequencing consumable revenue growing 29% from the second quarter,” said Francis deSouza, Chief Executive Officer. “We’re also making progress incorporating genomics into the standard of care in non-invasive pre-natal testing, oncology therapy selection, and genetic disease diagnosis. Looking forward, we believe our planned acquisition of GRAIL will catalyze a new era of early cancer detection, transforming cancer survivability and opening up the largest clinical application of genomics we’ve seen.”
As previously announced, Illumina has withdrawn its fiscal 2020 full year revenue and earnings per share guidance due to the uncertainties around the severity and duration of the COVID-19 pandemic.
For earnings history and earnings-related data on Illumina (ILMN) click here.